$34.22
0.672%
Last update: Nov 12, 7:30 AM
Harmony Biosciences Holdings Inc
HRMYNASDAQ
Harmony Biosciences rose 2.0% from $33.54 to $34.22, behind the S&P 500's +11.2%. Its worst day was Feb 20 (−15.2%), and its low came Mar 27 at $26.54.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Harmony Biosciences shares fell 6.6%, while the S&P 500 fell 0.2%.
−6.6% · S&P 500 −0.2%
EPS of $0.57 missed the $0.98 estimate on $243.8M revenue (est. $241.5M); FY revenue guidance of $1.0B–$1.0B against the $1.0B consensus.
Story events cover the past 12 months · Times ET
+4.9% · S&P 500 +0.7%
Harmony Biosciences closed at its lowest level of the year, 20.9% below where the year started.
−3.3% · S&P 500 −1.7%
Harmony Biosciences shares rose 8.8%, while the S&P 500 fell 0.7%.
+8.8% · S&P 500 −0.7%
EPS of $0.55 missed the $0.90 estimate on $215.4M revenue (est. $221.2M); FY revenue guidance of $1.0B–$1.0B against the $1.0B consensus.
−4.1% · S&P 500 −0.3%
Harmony Biosciences shares rose 10.0%, while the S&P 500 rose 0.8%.
+10.0%, the year's best day · S&P 500 +0.8%
EPS of $1.28 beat the $1.05 estimate on $261.3M revenue (est. $242.1M); FY revenue guidance of $1.0B–$1.0B against the $1.0B consensus.
+8.9% · S&P 500 +1.8%
Harmony Biosciences closed at its highest level of the year, 27.8% above where the year started.
+3.9% · S&P 500 +0.4%
EPS of $0.81 missed the $1.37 estimate on $268.9M revenue (est. $271.8M); FY revenue guidance of $1.0B–$1.0B against the $1.0B consensus.
−7.0% · S&P 500 +1.7%
Where it ended: a close of $34.22 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $1.43, revenue est. $282.2M).
Nothing in the past 12 months.
All HRMY dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for HRMY and SPY from Benzinga historical bars. Not investment advice.
